Innogene Kalbiotech Pte. Ltd.


Innogene Kalbiotech Pte. Ltd. (Innogene) is a research center in the field of biotechnology in Kalbe acquisition activity, as well as the development and commercialization of products. Among them, the research center has developed TheraCIM, monoclonal antibody products for cancer therapy as directed.

TheraCIM has completed phase 2 registration head and neck cancer, as well as the registration of clinical trials of cervical cancer. Innogene is starting the process of phase 3 head and neck cancer, and Phase 3 clinical trials for Racotumomab for non-small cell lung cancer (NSCLC). Up to now, Kalbe has registered TheraCIM in some countries such as Thailand, Myanmar, Indonesia, the Philippines and Cambodia, as well as obtain a Special Access Scheme (SMS) in Taiwan, Singapore, Malaysia and South Africa.


For further information, click

PT Pharma Metric Labs

Pharma Metric Labs is a Research Organisation outsourcing or Contract Research Organization (CRO) independent which provides services and services include Clinical Study Management, studies of bioavailability / Bioequivalence (BA / BE) and analysis of contracts for pharmaceutical companies in Indonesia and ASEAN to ensure that the results of clinical trials and registration at the authorized institutions quickly. Established in 2005 and began operations in 2006, PT Pharma Metric Labs is committed to providing accurate, reliable and timely cost effective for consumers. The headquarters is located in Jakarta, Indonesia with clinical facilities and integrated analysis. Bioanalytical Laboratory has gained accreditation to ISO / IEC 17025 / GLP and recognition from the Food and Drug Monitoring Agency (BPOM) Indonesia. Reports BA / BE produced has been delivered and accepted by BPOM (Indonesia), NPCB (Malaysia) and BFAD (Philippines) for the registration of new products.


PT Kalbio Global Medika


Established in January 2016, Joint-venture between the largest publicly – listed pharmaceutical company In Southeast Asia, PT Kalbe Farma Tbk and the leading South Korean biotechnology R&D company, GENEXINE Inc.

PT KALBE GENEXINE BIOLOGICS: The first biopharmaceutical Research & Development, clinical development and marketing investment of Indonesia. PT Kalbe Genexine Biologics will conduct research and development of new innovative biologic drugs which will be produced in Indonesia through PT Kalbio Global Medika a high tech biologics factory for marketing in Indonesia and the region. Through the formation of the joint venture company, Kalbe is gaining access to a wide range of next generation therapeutics proteins, access to advanced countries such as Australia and Taiwan and greater Foothold in existing market of ASEAN and Indonesia.

Stem Cell & Cancer Institute


Stem Cell and Cancer Institute is founded by Boenjamin Setiawan, MD, Ph.D, owner of PT Kalbe Farma in 2006. The Institute addresses aging related health issues, specifically regenerative medicine and cancer management. The vision of SCI is to be the best stem cell and cancer institute in Indonesia and beyond. And the mission is to conduct translational stem cell and cancer research through developing innovative and multidisciplinary collaborative approaches to improve the quality of life in ethical and responsible manner.

SCI lead by dr. Sandy Qlintang. Otherwise, there are 4 Principal Investigator, researchers and technicians who are divided into two divisions of research, namely the division of stem cells and cancer division


For further information, click